Genix Pharmaceuticals Corporation
GENPF · OTC
10/31/2024 | 10/31/2023 | 10/31/2022 | 10/31/2021 | |
|---|---|---|---|---|
| Market Cap | $3,302 | $2,465 | $4,406 | $8,789 |
| - Cash | $11 | $12 | $9 | $139 |
| + Debt | $816 | $512 | $183 | $49 |
| Enterprise Value | $4,106 | $2,965 | $4,579 | $8,700 |
| Revenue | $4 | $12 | $0 | $0 |
| % Growth | -67.2% | – | – | – |
| Gross Profit | $1 | $3 | -$564 | -$537 |
| % Margin | 32% | 26.4% | – | – |
| EBITDA | $49 | -$3,796 | -$434 | -$1,117 |
| % Margin | 1,211.3% | -30,743.3% | – | – |
| Net Income | -$73 | -$4,396 | -$1,074 | -$1,653 |
| % Margin | -1,806.9% | -35,600.3% | – | – |
| EPS Diluted | -0.001 | -0.074 | -0.018 | -0.028 |
| % Growth | 98.4% | -309.9% | 35.1% | – |
| Operating Cash Flow | -$187 | -$221 | -$220 | -$428 |
| Capital Expenditures | $0 | $0 | -$3 | $0 |
| Free Cash Flow | -$187 | -$221 | -$223 | -$428 |